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T
he Pt-based anticancer compounds,
including cisplatin, carboplatin, ox-
aliplatin, and nedaplatin, exert their
antitumor activity by binding to DNA and
promoting cell death.17 In the presence of
high chloride concentrations (e.g., human
plasma), cisplatin (cis-Pt(NH3)2Cl2) exists
mostly in its neutral form. However, in solu-
tions with lower chloride concentration,
the drug goes through a multistep hydroly-
sis, producing the charged species, cis-
[Pt(NH3)(H2O)Cl] and cis-[Pt(NH3)2(H2O)2]2,
and their deprotonated products, cis-
[Pt(NH3)(OH)Cl], cis-[Pt(NH3)2(OH)(H2O)], and
cis-[Pt(NH3)2(OH)2].13 All of these species may
interact with nitrogen atoms of the bases of
nuclear DNA, forming mono- and bidentate
adducts, that is, monohydroxy or dihydroxy
cisplatin complexes that can further bind to
nitrogen atoms of DNA by losing their hy-
droxyl groups; the resulting “Pt lesions” im-
pair DNA functions and induce cell death
most likely through apoptotic pathways.17
Structurally, transplatin (trans-Pt(NH3)2Cl2) dif-
fers from its cis-isomer in the arrangement of
the ligands around Pt in these square planar
compounds. This alteration makes transplatin
much less lethal than cisplatin, possibly be-
cause of the restricted access to DNA due to
steric hindrance.8,9 Our previous studies re-
vealed that cisplatin impairs cellular respira-
tion in a dose-dependent and time-
dependent manner by inducing intracellular
caspase activity, whereas its trans-isomer ex-
erts no observable inhibition of mitochon-
drial oxygen consumption.6,7
Mesoporous silica microparticles (MSMs)
are a class of nanostructured materials with
nanometer pores that are currently thought
to have potential applications as drug deliv-
ery vehicles because of their large surface
area, high pore volume, and tunable nano-
scale pores.1019 Previously, we investigated
the adsorption and release of drug mol-
ecules including isomeric platinum drugs
by mesoporous materials.10,11 The two most
common types of mesoporous materials,
SBA-15 and MCM-41, exhibited different ad-
sorption and release profiles for both cis-
or trans-platin.11 Furthermore, the two ma-
terials showed dissimilar capacity in hosting
the cisplatin and transplatin isomers.11 The
difference in drug encapsulation and re-
lease shown by the materials for the two
isomers of the platinum drug can be ex-
pected to induce different therapeutic ef-
fects. We also have recently showed the ef-
fect of MCM-41 and SBA-15 on
mitochondrial O2 consumption (respira-
tion) of HL-60 (myeloid) cells, Jurkat (lym-
phoid) cells, and isolated mitochondria.20
While SBA-15 showed a concentration- and
time-dependent inhibition of cellular respi-
ration at 25500 g/mL, MCM-41
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ABSTRACT We report on the endocytosis and the time-dependent enhanced cytotoxicity of anticancer
platinum drugs when the drugs are combined with (or loaded into) one of the two most common types of
mesoporous silica materials, MCM-41 or SBA-15. The anticancer drug cisplatin and its isomer transplatin, when
loaded on MCM-41 and SBA-15 microparticles, were less cytotoxic to leukemia cells than the drugs alone after 12 h
exposure. However, the drug-loaded microparticles exhibited unprecedented enhanced cytotoxicity to the
cancerous cells after 24 h of exposure. This cytotoxicity of the drug-loaded microparticles was even higher than
of the pure drugs in solutions, suggesting that mesoporous silica microparticles loaded with cisplatin or transplatin
enabled a localized intracellular release of the platinum compounds and possibly also facilitated the drug’s
hydrolysis, enhancing the desired cytotoxic effect.
KEYWORDS: mesoporous materials · nanomaterials · adsorption
capacity · endocytosis · cell viability
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exhibited no noticeable effect on the cell res-
piration rate. Both materials, however, inhib-
ited the respiration rates of isolated mitochon-
dria and submitochondrial particles with no
harm to their cellular glutathione.20 In another
study, we also demonstrated that a high dos-
age of organic-functionalized mesoporous
materials could result in cancerous cell
death.21
Herein we report on an unprecedented
higher cytotoxicity of platinum drug/mesopo-
rous microparticles combination on cancer
cells, more than the sum of the cytotoxicity
of the drug and that of the microparticles.
Platinum drug-loaded MSMs were prepared
using either MCM-41 or SBA-15. The synthe-
sized particles were calcined to remove the
templates, followed by a series of characteriza-
tions, including transmission electron micros-
copy (TEM), nitrogen physisorption, and el-
emental analysis. Cell uptakes of both SBA and
MCM particles were next examined and dem-
onstrated by TEM images. As a possible conse-
quence of endocytosis, the cytotoxicity of
drug-loaded particles to Jurkat (leukemia) cells
was assessed. The drug-loaded microparticles
showed an enhanced cytotoxicity to cancer
cells after 24 h incubation, compared to either
the particles or the drug alone. The cytotoxic
effect by the drug and microparticles was
higher than the simple sum of cytotoxicities
of the drug and the particles. Interestingly,
even the less potent transplatin became very
cytotoxic when delivered by MSMs. This is the
first report that illustrates the enhancement
of cytotoxicity of cisplatin or transplatin by using meso-
porous microparticles as drug delivery systems.
RESULTS AND DISCUSSION
MSMs, whose organic templates were removed by
calcination, were first synthesized as described in the
Methods section. They were then characterized by TEM
(as shown in Supporting Information Figure S1). TEM
images show that the calcined MCM-41 materials con-
tain rather regular particles of 500900 nm with a
spherical or oval shape, while the calcined SBA-15 ma-
terials possess irregularly shaped and micrometer-sized
particles of various diameters. The materials were fur-
ther characterized by nitrogen physisorption measure-
ments (Table S1 and Figure S2), which gave type IV iso-
therms with steep capillary condensation steps for
both materials, confirming the presence of highly or-
dered mesoporous structures with high surface areas.
The surface areas were 876 and 1216 m2/g for MCM-41
and SBA-15 samples, respectively. Furthermore, both
samples possessed a high pore volume of quite similar
value of 0.9 cm3/g. However, as expected, the pore di-
ameter of MCM-41 was about two times smaller than
that of SBA-15, with values of 59.3 and 28.7 Å, respec-
tively. Elemental analyses of calcined MSMs (Table S2)
corroborate the successful removal of surfactants, elimi-
nating the possibility of further induced cytotoxicity by
the templating reagents.
The internalization of MSMs was next investigated
and demonstrated by TEM images (Figure 1 and Sup-
porting Information Figure S3). To examine the cellular
uptake of these particles, 0.5  106 Jurkat cells/mL were
incubated with 200 g/mL of SBA-15 or MCM-41 at 37
°C for 1 h, kept gently stirring. At the end of incubation,
1.5-mL cell suspensions were collected, processed, and
visualized by TEM (see Methods for details). As shown in
Figure 1, it is obvious that both mesoporous SBA-15
and MCM-41 microparticles can be efficiently ingested
by cells, although the uptake pathways appear to be
different. This agrees with the report on endocytosis of
MSMs that described the internalization of particles
within a short time of exposure in human lung cancer
cells (A549).19,22 However, it is worthwhile to note that
the ingestion of MCM-41 particles by Jurkat cells re-
Figure 1. TEM images show the internalizations of SBA-15 (A) and
MCM-41 (B) by Jurkat cells. Arrows indicate the intracellular distribu-
tions of microparticles. Circles in panel A (upper, right panel) show the
early formation of endosomes, characteristic of a receptor-mediated
endocytosis.
A
RT
IC
LE
VOL. 4 ▪ NO. 2 ▪ TAO ET AL. www.acsnano.org790
sulted in a pseudopodium folded by cell
membrane, indicating a possible phagocyto-
sis, whereas cell uptake of SBA-15 suggested a
receptor-mediated endocytotic process, typi-
fied by a formation of intracellular endosomes
as indicated in Figure 1A (upper right and
lower left panels). The difference in the up-
take mechanism for these two mesoporous
microparticles could be mainly a result of their
different shapes rather than their distinctive
mesopore sizes (the pore size of SBA-15 is
twice as large as that of MCM-41).
Given the possibility that the cellular up-
take of microparticles themselves could lead
to severe cytotoxicity, Jurkat cells were incu-
bated with and without 200 g/mL of SBA-15
or MCM-41 at 37 °C for 24 h (Figure 2). As a
negative control, 20 M doxorubicin was
added separately into cell suspension. As a
potent antitumor agent, doxorubicin executes
cell death by inducing caspase activation and
impairing mitochondrial respiration.7,23 It is
also worth mentioning that the delivery of
doxorubicin aided by nanomaterials has re-
cently been reported by a few research
groups.24,25 However, the possible enhance-
ment of drug cytotoxicity by the drug / nano-
materials combination compared to the drug
or the materials alone as we had observed
here was not reported to be the case for dox-
orubicin in these previous recent reports.24,25
Although a doxorubicin/MSM combination
was not studied here, doxorubicin was used as a con-
trol to verify the cell viability tests. Cell viability was
found to be 100  12.4% for untreated cells, 1.6  0.7%
for 20 M doxorubicin-treated cells (p  0.001), 71.6
 7.2% for 200 g/mL of SBA microparticle-treated cells
(p  0.01), and 82.0  7.5% for 200 g/mL of MCM
microparticle-treated cells (p  0.03) (Figure 2A). Hence,
at a dosage of 200 g/mL, the cytotoxicities of mesopo-
rous MCM-41 and SBA-15 microparticles on Jurkat cells
are small, making both materials good candidates for
drug carriers. Note that this cytotoxicity could not re-
sult from the physical wrapping or surrounding of the
cell by microparticles because cytotoxicity in adhesive
cell lines was unchanged when the particles were lay-
ered first in the well.26,27
Cisplatin and transplatin were next loaded on ei-
ther SBA-15 or MCM-41, and the cytotoxicities of the
drug-loaded microparticles were then analyzed. First, a
5 mg/mL SBA-15 or MCM-41 suspension was soaked in
1 mM cisplatin or transplatin solution in PBS for 48 h,
with continued stirring. Afterward, 4 L of the
drugmicroparticle mixture was added to a 100-L
Jurkat cell solution (equivalently, 8000 cells were ex-
posed to 200 g/mL microparticles plus 40 M plati-
num drugs). In parallel, cells were incubated with 40 M
cisplatin or transplatin previously aged in PBS for 48 h
(i.e., hydrolysis of drugs is complete). Cell viability was
checked in each condition at 12 and 24 h incubation.
Results are shown in Figure 2B.
At 12 h (solid bars), cell viability was 100  3.2% for
untreated cells, 15.1  2.9% for cisplatin-treated cells
(p  0.001), 83.8  5.9% for cisplatin  SBA-treated
cells (p  0.001), 78.5  6.7% for cisplatin  MCM-
treated cells (p  0.03), 67.7  13.9% for transplatin-
treated cells (p  0.01), 106.2  9.5% for transplatin 
SBA-treated cells (p  0.01), and 105.6  13.3% for
transplatin  MCM-treated cells (p  0.01). At a concen-
tration of 40 M, cisplatin exhibited a significant toxic-
ity to Jurkat cells in 12 h incubation, inactivating 84.9%
of the cells. Transplatin was much less toxic: only 32.3%
of cells were killed. Furthermore, packaging drug in
MSMs decreased the drug cytotoxicity in the first 12 h.
In the presence of cisplatin, either SBA-15 or MCM-41
protected cells from the treatment for the first 12 h.
Forty micromolar transplatin had also very little effect
on cancer cells in 12 h, and loading transplatin on MSM
microparticles made the effect even smaller. Thus, both
MSMs protected cells from chemotherapy for the first
12 h. This is most probably because the diffusion of the
drug-loaded microparticles into the cell occurred much
Figure 2. (A) Cell viability after 24 h incubation of 6000 Jurkat cells with no drug, 20
M doxorubicin, 200 g/mL of SBA-15, and 200 g/mL of MCM-41 microparticles. (B)
Cell viability after 12 h (filled) or 24 h (open) incubation of 8000 Jurkat cells with no drug,
40 M cisplatin alone or with 200 g/mL of SBA-15 or MCM-41, 40 M transplatin alone
or with 200 g/mL of SBA-15 or MCM-41.
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slower than the diffusion of the naked drug. Further-
more, there is the possibility of the slow intracellular re-
lease of the MSM-adsorbed drugs. Consequently, the
cytotoxic effects of these drug-loaded microparticles
were postponed. Interestingly, however, after a total
24 h incubation (open bars), these drug-loaded micro-
particles showed a significantly enhanced cytotoxicity,
more so than the drug or the particles alone. Cell viabil-
ity after 24 h was found to be 100  18.8% for un-
treated cells and 6.9  13.3% for cisplatin-treated cells
(p  0.001). The combination of cisplatin with either
SBA-15 or MCM-41 caused complete cell death, as no
absorbance corresponding to living cells was read. The
calculated viability for cisplatin  SBA at 24 h is 12.3
 20.1% and for cisplatin  MCM 6.8  11.8%, both
essentially zero (see Figure 2B). Thus, the microparticles
enhance cell killing by cisplatin. For transplatin-treated
cells, cell viability became 45.9  13.6% (p  0.01).
Transplatin had an inhibitory effect on cell growth, al-
though less acute and lethal than its cis-isomer. How-
ever, only 2.6  26.7% transplatin  SBA-treated cells
(p  0.02) and 12.7  10.1% transplatin  MCM-treated
cells (p  0.01) survived the 1 day treatment. The large
errors reflect the variable degree of inhibition of par-
ticles on cell survival.20 Since we indicated that MSM it-
self had a limited cytotoxicity as we showed above or
reported previously,20,27 it was apparent that the MSM
greatly augmented also the cytotoxicity of transplatin,
as it did for cisplatin. This is possibly because the mate-
rials may have assisted transplatin in reaching an intra-
cellular site or even increased its hydrolysis, leading to
more toxicity. We recently found out that mesoporous
materials could accelerate the oxidation of epinephrine
(a hormone molecule), perhaps due to the formation
of hydroxyl or oxygen radicals in their mesoporous
channels.28 Therefore, the possible generation or pres-
ence of free radicals in MSMs in aqueous solutions
could potentially also catalyze the hydrolytic reactions
of platinum drugs, which in turn lead to their enhanced
pharmaceutical effects. It is worth noting again that
the hydrolysis reactions of cis- and trans-platinum drugs
involve the substitution of chloride(s) by hydroxyl
groups.13
CONCLUSIONS
In this study, we reported on the cytotoxicity and
the associated pharmaceutical effect of drug/MSMs
combination compared to the drug or MSMs alone.
The drug-loaded materials exhibited much improved
antitumor activities, more than either the drug or the
material alone, and this enhanced anticancer activity
appears to be much more than the simple sum of the
cytotoxicities of the particles and the drug. This is the
first time that an enhanced anticancer property on ma-
lignant cells by combining platinum compounds with
mesoporous silicates has been demonstrated. It is also
of great importance that, with a much lessened potency
when compared to its renowned cis-isomer, even trans-
platin exhibited a surprisingly high cytotoxicity when
it is combined and delivered with these nanostructured
materials. Transplatin has been traditionally known to
be inactive and has, therefore, been not so useful for
cancer treatment, but when loaded on mesoporous
silica particles, it can be made to have an unprec-
edented high anticancer property, almost to the same
magnitude as cisplatin. Also, the particles probably pro-
tect transplatin from hydrolysis (its hydrolysis rate is
larger than that of cisplatin because of the trans effect)
and subsequent reactions with extracellular species;
when it is released inside the cell, it can readily react
with DNA and other intracellular species and cause cell
death.34 This work shows that drugs and even less po-
tent drug isomers can become effective and valuable
pharmaceuticals by proper combination with micro- or
nano-sized materials. It appears that the drug-loaded
mesoporous silica SBA-15 and MCM-41 microparticles,
after entering cells, release the encapsulated platinum
drugs and increase their potency, possibly by improv-
ing localized drug delivery or targeting as well as facili-
tating their drug hydrolysis.
METHODS
Materials and Reagents. Cetyltrimethylammonium bromide
(CTAB), tetraethylorthosilicate (TEOS), and poly(ethylene oxide)-
block-poly(butylene oxide)-block-poly(ethylene oxide) (Pluronic
P123 or P123, MW  5800) were obtained from Sigma-Aldrich.
Cisplatin (Cis) and transplatin (yellow powder, MW  300.05)
(Trans) were obtained from Sigma-Aldrich and dissolved in PBS
before experiments. Phosphate-buffered saline (1 PBS, without
Mg2 and Ca2, pH  7.4) was purchased from Mediatech (Hern-
don, VA). Doxorubicin HCl (3.45 mM) was purchased from Bed-
ford Laboratories (Bedford, OH).
Synthesis of SBA-15 and MCM-41. Mesostructured MCM-41- and
SBA-15-type materials were synthesized by previously reported
procedures with minor modification.2933 For the MCM-41 syn-
thesis, 11.0 mmol CTAB was mixed with 960 mL of distilled wa-
ter (dH2O) and 14 mL of 2.0 M NaOH solution and stirred at 80 °C
for 30 min. Then 101.2 mmol TEOS was slowly dripped into the
reactant solution, which was stirred for another 2 h at 80 °C. It
was filtered when still hot, and the solid was washed with copi-
ous amounts of dH2O and ethanol. The resulting precipitate was
dried in an 80 °C oven overnight, which gave the MCM-41 “as
synthesized”. To remove the surfactant template from the ma-
terial, as-synthesized MCM was calcined at 550 °C for 5 h (heat-
ing rate  1 °C min1). The resultant CTAB-free mesoporous silica
MCM-41 was then collected.
To synthesize SBA-15-type mesoporous silica material, 1.4
mmol (8 g) Pluronic P123 was dissolved in a mixture of 60 mL
of distilled water and 240 mL of 2 M HCl that was prewarmed at
40 °C and stirred for 4 h until no longer chunky. Then 81.7 mmol
of TEOS was added into the solution while stirring at 40 °C for
20 h. The mixture was then moved to an 80 °C oven to age for
24 h under static conditions. After that, 20 mL of ethanol was
added and mixed well. The solution was filtered, and the cake
was washed with distilled water 45 times (20 mL each time).
The precipitate was then left to dry overnight, producing as just
synthesized SBA-15 material, which was further calcined at 600
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°C for 5 h (heating rate  1 °C min1) to remove P123, finally
making SBA-15.
Cell Image by TEM. T-cell lymphoma (Jurkat) cells were pur-
chased from American Tissue Culture Collection (Manassas, VA)
and cultured in RPMI-1640 media plus 10% fetal bovine serum,
1% L-glutamine, and 1% penicillin/streptomycin. Cell count and
viability were determined by light microscopy, using a hemocy-
tometer under standard trypan blue staining; 0.5 million Jurkat
cells/mL were incubated with 200 g/mL calcined SBA-15 or
MCM-41 for 1 h, kept gently stirring. Then, 1.5 mL cell suspen-
sions were then collected and centrifuged. The cell pellets were
soaked with 2.0% glutaraldehyde in 0.1 M cacodylate buffer (BOC,
pH  7.4) for 2 h at 4 °C. The cell pellets were rinsed three times
within the same BOC buffer, each time by 10 min centrifuge. After
careful washing, the cell pellets were mixed in BOC with 1% os-
mium tetroxide (OsO4) for 1 h at 4 °C, followed by three times BOC
washing again. The resulting cell pellets were mixed with 2% agar-
ose, forming jello-like cell samples. The cell samples were cut into
pieces and subsequently dehydrated in 25% (10 min), 50% (10
min), 75% (overnight), 95% (10 min), 100% (10 min), and 100% (10
min, a second time) ethanol. The polymerization process was com-
pleted by embedding cell samples in resin plates, infiltrated with a
series of mixtures of resin and polyepoxide at ratios of 2:1 (4 h),
1:1 (4 h), and 1:2 (4 h), ending with 100% polyepoxide (4 h). The
samples were then microtomed for TEM.
Cytotoxicity Assay In Vitro. Cytotoxicities of either MSM or MSM
loaded with platinum compounds were evaluated on Jurkat
cells by using the standard cell counting kit (CCK-8, Dojindo Mo-
lecular Technologies, Inc., Rockville, MD) as previously reported.27
A 96-well plate was utilized for the cell placement; 100 L/well
cell-free media or cell suspension (cell density  4000 cells per
well) was distributed into a row of at least 6 wells for statistical
purpose (n  612). MSM plus either cisplatin or transplatin was
then added according to the experimental designs. Plates were
incubate at 37 °C with 5% CO2 for 12 h, followed by adding 10 L
of WST-8 agent (i.e., 2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium
salt), which can be bioreduced by cellular dehydrogenases to a
water-soluble orange formazan product. The amount of this for-
mazan product will be proportional to the number of living
cells. After another 2 h incubation, the absorbance (Abs) was
measured at 450 nm using a microplate reader. Cell viability was
expressed as {(Abstreated  Absmedia/Absuntreated  Absmedia)  stan-
dard deviation}%.
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